777 abstracts found.



Results filter

Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma (HL) and a negative PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial

Year:

Session type:

John Radford1, Sally Barrington2, Nicholas Counsell3, Ruth Pettengell13, Peter Johnson4, Jennie Wimperis5, Stewart Coltart6, Dominic Culligan7, Andrew Lister8, Eric Bessell9, Anton Kruger10, Bilyana Popova3, Barry Hancock11, Peter Hoskin12, Tim Illidge1, Mike O'Doherty2
1The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, 2PET Imaging Centre, St Thomas' Hospital, London, UK, 3Cancer Research UK and UCL Cancer Trials Centre, London, UK, 4University of Southampton, Southampton, UK, 5Norfolk and Norwich University NHS Foundation Trust, Norwich, UK, 6Kent and Canterbury Hospital, Canterbury, UK, 7Aberdeen Royal Infirmary, Aberdeen, UK, 8Barts and the London School of Medicine, London, UK, 9Nottingham City Hospital, Nottingham, UK, 10Royal Cornwall Hospital, Truro, UK, 11University of Sheffield, Sheffield, UK, 12Mount Vernon Cancer Centre, Northwood, UK, 13St George's, University of London, London, UK

Development of a microfluidic device to assess procoagulant activity in ovarian cancer in response to treatment with chemotherapeutic agents

Year:

Session type:

Kathryn Date1, Yuehua Dou1, Marina Flynn2, Leigh Madden1, John Greenman1
1University of Hull, Hull, UK, 2Castle Hill Hospital, Hull, UK

Evaluation of multiple drug resistance in acute leukemia by real time PCR (RT-PCR)

Year:

Session type:

Eman Mosad1, Rania M Bakry1, Eman Hassan1
1South Egypt Cancer Institute, Assiut, Egypt

Glycoproteomics identifies cadherin-5 as a novel serum biomarker of metastatic breast cancer

Year:

Session type:

Simon Fry1, John Sinclair2, John Timms2, Anthony Leathem2, Miriam Dwek1
1University of Westminster, London, UK, 2University College London, London, UK

DNA repair proteins XPF and MUS81 are predictive biomarkers for oxaliplatin-fluorouracil chemotherapy in patients with oesophageal cancer

Year:

Session type:

Thomas MacGregor1,2, Richard Gillies2, Natasha Sahgal3, Rebecca Carter1, Runjan Chetty4, Lai-Mun Wang4, Nicholas Maynard2, Peter McHugh5, Mark Middleton1, Ricky Sharma1
1Department of Oncology, Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK, 2Department of Upper GI Surgery, Churchill Hospital, OUH NHS Trust, Oxford, UK, 3Wellcome Trust Centre for Human Genetics, Oxford, UK, 4Oxford NIHR Biomedical Research Centre/Department of Cellular Pathology OUH NHS Trust, Oxford, UK, 5Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK

International Cancer Benchmarking Partnership (ICBP) Module 4: Root Causes of Diagnosis and Treatment Delay in Four Cancer Sites: Lessons Learnt from the Northern Ireland Pilot Study

Year:

Session type:

Jackie Boylan1, Anna Gavin1, Conan Donnelly1, Module 4 Working Group2
1Queen's University Belfast, Belfast, UK, 2ICBP Module 4 Working Group, Canada, Australia, UK, Norway, Denmark, Sweden, UK

Neoadjuvant chemotherapy and prognostic subgroups defined by survival benefit in patients with locoregionally advanced nasopharyngeal carcinoma

Year:

Session type:

Messaoud Ayad1, Kahina Rabahi1, Kada Boualga1
1Centre Anti-Cancer, Blida, Algeria

Page 78 of 78« First...25...78